Carmil Therapeutics is developing a unique technology to enhance the efficacy of cell therapies based on therapeutic T lymphocytes for the treatment of cancer and autoimmune diseases (e.g., CAR-Ts, TILs).
Carmil modifies these T cells with a gene that gives them the ability to trigger the CD28 costimulatory signal even without the CD80/CD86 ligands. This enables T cells to be more effective in low-inflammatory environments and to possess intrinsic resistance to several inhibitory signals induced by the tumor microenvironment (CTLA-4, PD1). In addition, this technology addresses many of the challenges encountered by CAR-T cells (Chimeric Antigen Receptor engineered T cells) or TILs (Tumour Infiltrating Lymphocytes) in the treatment of solid tumors. The company is currently at the pre-clinical stage, developing several programs in the field of solid tumors and autoimmune disorders.